GleamWall
中文EN

RLYB Rallybio Corp

Pharmaceutical Preparations · Nasdaq · SEC CIK 1739410 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-32.0%
TTM net income YoY289.2%
TTM EPS YoY145.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-5,580.9%
Net margin6,177.4%
FCF margin—
EBITDA margin-5,579.0%

Returns

ROE34.5%
ROA32.8%
ROIC (approx.)-149.0%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets3.4%
Debt / equity0.00x
Current ratio28.87x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.16x
Accruals ratio-5.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$212,000$222,000$212,000$212,000$212,000$2,000
R&D expense$584,000$758,000$2.87M$3.65M$4.14M$6.07M$5.72M$7.38M
SG&A expense$2.84M$4.89M$6.07M$2.98M$2.99M$4.20M$4.16M$4.26M
Operating income-$3.42M-$5.65M-$8.73M-$6.41M-$6.92M-$10.06M-$9.67M-$11.61M
Pretax income-$2.65M$44.99M-$8.28M-$6.73M$16.02M-$9.42M-$8.85M-$10.61M
Income tax$80,000$1.32M—$0$0$0——
Net income-$2.73M$43.66M-$8.28M-$5.85M$16.02M-$9.70M-$9.44M-$11.04M
EBITDA-$3.42M-$5.65M-$8.73M-$6.41M-$6.89M-$10.03M-$9.64M-$11.58M
EPS (basic)-0.487.66-1.46—2.84-1.73-1.69—
EPS (diluted)-0.487.53-1.46—2.84-0.22-1.69—
Weighted avg. shares (diluted)5.72M5.80M5.69M—5.63M44.84M5.60M—
Balance sheet
Cash & equivalents$90.69M$92.85M$41.30M$31.37M$32.12M$9.45M$14.78M$13.90M
Short-term investments$0$0$5.50M$23.36M$27.20M$36.30M$39.72M$51.61M
Current assets$94.77M$97.25M$53.49M$61.25M$66.63M$50.27M$57.38M$67.84M
PP&E, net$0$0$20,000$23,000$26,000$61,000$87,000$115,000
Total assets$95.58M$98.06M$54.47M$62.26M$67.66M$51.00M$57.98M$68.11M
Current liabilities$3.28M$3.57M$4.14M$4.22M$4.52M$5.04M$3.91M$6.24M
Total liabilities$3.28M$3.57M$4.20M$4.30M$4.63M$5.04M$3.91M$6.45M
Shareholders' equity$92.30M$94.50M$50.28M$57.96M$63.03M$45.96M$54.07M$61.65M
Shares outstanding5.33M5.31M5.29M5.28M41.94M41.71M41.61M5.19M
Cash flow statement
Operating cash flow-$2.28M$45.92M-$7.98M-$4.68M-$6.55M-$8.38M-$10.21M-$9.86M
Investing cash flow$0$5.50M$17.90M$3.92M$29.23M$3.04M$11.08M-$1.57M
Financing cash flow$120,000$131,000$3,000$6,000$0$10,000$0$18,000
Depreciation & amortization$0$2,000$3,000$3,000$35,000$26,000$28,000$30,000
Stock-based compensation$405,000$424,000$613,000$774,000$1.05M$1.61M$1.88M$1.96M

Free plan shows the latest 8 periods; Pro shows all 26 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.